Developing Novel Antimicrobials by Synthetic Biology (360G-Wellcome-102411_Z_13_Z)
Current problems with increasing antimicrobial resistance mean the discovery of novel antimicrobials is becoming increasingly important. Therefore, antimicrobial drug discovery has been selected as a model to investigate the feasibility of using synthetic biology to create azol(in)e modified peptide libraries and select mutants with biological activity. The library of azol(in)e modified peptides will be created by engineering Escherichia coli to express; heterocyclisation enzymes and a mutated array of substrate peptides. The library will undergo a selection methodology to detect mutants which show antimicrobial activity against a target bacterial overlay e.g. Mycobacterium tuberculosis. Once identified, the large scale biological production and potency optimisation of discovered antimicrobial compounds will be conducted.
Where is this data from?
This data was originally published by The Wellcome Trust. If you see something about your organisation or the funding it has received on this page that doesn't look right you can submit a grantee amendment request. You can hover over codes from standard codelists to see the user-friendly name provided by 360Giving.
Grant Details
| Amount Awarded | 163023 |
| Applicant Surname | Coates |
| Approval Committee | PhD Studentships |
| Award Date | 2013-06-24T00:00:00+00:00 |
| Financial Year | 2012/13 |
| Grant Programme: Title | PhD Studentship (Basic) |
| Internal ID | 102411/Z/13/Z |
| Lead Applicant | Mr John Coates |
| Partnership Value | 163023 |
| Planned Dates: End Date | 2017-03-31T00:00:00+00:00 |
| Planned Dates: Start Date | 2013-09-23T00:00:00+00:00 |
| Recipient Org: Country | United Kingdom |
| Region | Greater London |
| Sponsor(s) | Prof Gabriel Waksman |